๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II evaluation of menogaril in patients with advanced cervical carcinoma

โœ Scribed by Harry J. Long; Harry S. Wieand; John F. Foley; Robert D. Niedringhaus; John A. Laurie; Roscoe F. Morton; Richard M. Goldberg; James A. Mailliard; George D. Malkasian; John H. Edmonson

Publisher
Springer US
Year
1991
Tongue
English
Weight
170 KB
Volume
9
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

Fourteen patients with advanced/recurrent squamous cell carcinoma of the uterine cervix received menogaril, 200 mg/m 2 by one hour intravenous infusion at four-week intervals. No objective regressions were observed. Median time to progression was less than two months and median survival was seven months. All patients experienced neutropenia. Platelet toxicity was negligible. Venous irritation and phlebitis occurred at the infusion site in 4307o of patients. Menogaril as administered in this protocol is ineffective in treating previously irradiated advanced/recurrent squamous cell carcinoma of the uterine cervix and warrants no further investigation in this disease at the dosage and administration schedule used in this protocol.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of menogaril in advanced
Phase II trial of menogaril in advanced colorectal cancer
โœ Eduard E. Holdener; Wim W. Bokkel Huinink; Genevieve Decoster; Christian Ludwig; ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 262 KB

Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were ach

Phase II evaluation of dianhydrogalactit
Phase II evaluation of dianhydrogalactitol in the treatment of advanced non-squamous cervical carcinoma
โœ Frederick B. Stehman; John A. Blessing; Howard D. Homesley; John L. Currie; Edga ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› Springer US ๐ŸŒ English โš– 139 KB

In an on-going Phase II evaluation, dianhydrogalactitol (NSC 132313) was administered intravenously to 28 patients with advanced or recurrent non-squamous cell carcinoma of the cervix. The initial dosage was 60 mg/m 2/wk with escalation to 75 mg/m z/wk if there were no adverse effects. Twenty-seven

Phase II study of spirogermanium in pati
Phase II study of spirogermanium in patients with advanced colorectal carcinoma
โœ Jaffer A. Ajani; Jack S. Faintuch; Roxann K. McClure; Bernard Levin; Bruce M. Bo ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› Springer US ๐ŸŒ English โš– 193 KB

Twenty one evaluable patients with advanced colorectal carcinoma were treated with continuous infusion of spirogermanium at a median daily dose of 150 mg/rn 2 (range 120-210) for five consecutive days every 14 days. Treatments were accomplished by using outpatient infusion devices. Fifteen patients